1

2

7:30 – 8:45 am Registration

8:45 – 9:15 am

Welcoming Remarks Weiguo Dai, SAPA President Qiyue Zhang, Consul General, Chinese Consulate General in New York

Plenary Session Ballroom West and Center

Keynote presentations will focus on the key drivers in transforming global drug development, from breakthrough technologies and innovative therapies to regulatory sciences, capital investment and legal protection. These distinguished leaders will share their perspectives on current state of the art approaches and discuss next generation strategies and technologies.

9:15 – 9:45 am Isaac Blech, Managing Director, 21st Century Investors Group 9:45 – 10:15 am Josh Ghaim, Chief Technology Officer, Johnson & Johnson

10:15 – 10:30 am Coffee Break

10:30 – 11:00 am Lawrence Yu, Deputy Director, Office of Pharmaceutical Quality, FDA 11:00 – 11: 30 am Axel Hoos, SVP, Oncology R&D, GSK 11:30 – 12:00 pm Sandra Leung, EVP, General Counsel and Corporate Secretary, BMS

12:00 – 1:00 pm Lunch Miradelle

Session A-1 Immuno-Oncology: the Latest Development

Ballroom West

Immuno-oncology represents a revolutionary and innovative approach to cancer treatment that seeks to activate the body’s own immune system to combat tumors. The session will offer an update on the latest trend and advancement in immuno-oncology. Leading experts and key opinion leaders will present cutting edge research in world renounced academic laboratories, new R&D model and strategies of immune-oncology drug discovery in leading Pharma, innovative therapy developed by a biotechnology firm and the research portfolio supported by patient oriented non-profit organizations.

1:00 – 1:25 pm Litao Zhang, VP, Leads Discovery and Optimization, BMS 1:25 – 1:50 pm Lee Greenberger, CSO, The Leukemia & Lymphoma Society 1:50 – 2:15 pm Daniel O'Conner, CEO, Advaxis, Inc 2:15 – 2:40 pm Speaker from Professor Carl June’s Lab, University of Pennsylvania

2:40 – 3:00 pm Coffee Break

Session A-2 Precision Medicine – Current Landscape and Global Initiatives

Recent advancement in genomics, biomarkers, big data have meant that some of the fundamental challenges of precision medicine are being realized. In his 2015 State of the Union address, President Obama unveiled an ambitious Precision Medicine

Open for registration

3

Initiative promising new discoveries and treatments toward improved healthcare. Early 2016, China also announced a $9.2 Billion, 15-year initiative that will establish the country as a leader in precision medicine. In both public and private sector, "precision medicine” will now undoubtedly become the standard for the future of healthcare. With an educational goal, this session aims to interrogate “Precision Medicine” from diverse perspectives of multiple key players in the industry. How does the pharmaceutical industry leverage “precision medicine” to develop better and more precise therapeutics for targeted patient populations? How can molecular diagnostic firms leverage emerging policies and technologies to develop companion diagnostics to support development of “precision medicine”? What are the opportunities and challenges of the Chinese “Precision Medicine Initiative" as compared to its US counterpart? Recognized leaders from multiple sectors in the industry share their insights about precision medicine and will present a valuable session appealing to a wide audience.

3:00 – 3:25 pm Yiwu He, Global R&D Head, BGI Genomics 3:25 – 3:50 pm Sean Hu, SVP, Head of Consulting, Americas Pharmaceutical and Diagnostics,

GlobalData 3:50 – 4:15 pm Kamala Maddali, VP, Cancer Genetics

Session B Global Innovation

Ballroom Center

In a recent report about the innovation capacity among G20 industrial countries, US garners the first place and China marks the ninth. In pharmaceutical industry, China has been transforming itself from being a manufacturer to an innovator. We have witnessed the dramatic advancement of technology in both US and China through international collaboration over the past decades, a role that is central to SAPA. In addition to its business impact, innovation could profoundly affect the health of citizens. It is the duty of pharmaceutical professionals to accelerate global innovation, especially targeting the un-met medical needs. SAPA is fortunate to invite the following distinguished presenters who will interpret the trend of global pharmaceutical innovation from different angles: a professor from academia, an executive from a multi-national company, an outstanding entrepreneur, leaders from international scientific organizations.

1:00 – 1:25 pm Niya Brower, Deputy Director in CMC, Bill & Melinda Gates Foundation 1:25 – 1:50 pm Fener Chen, Professor and Member of Chinese Academy of Engineering, Fudan

University

1:50 – 2:15 pm Chris Molineaux, President, PA Bio 2:15 – 2:40 pm Sudip S. Parikh, SVP & Managing Director, DIA

2:40 – 3:00 pm Coffee Break

3:00 – 3:25 pm Michael Yu, President and CEO, Innovent Biologics, Inc. 3:25 – 3:50 pm Yongkui Sun, 美国工程学院院士

3:50 – 4:15 pm Dan Zhang, CEO, Fountain Medical Development Ltd.

4

Session C-1 Deluxe Executive Parior 166

Venture Capital (VC) Roundtable Discussion

Do you want to become an entrepreneur and capitalize on your innovative technology or idea(s), but wonder: how to start your own business, where and how to obtain your “first bucket of gold” to start the business, or how to prepare a winning business plan that will withstand potential investors’ scrutiny? If you are an experienced entrepreneur that has already achieved the early stages of success, are you interested in where and how to obtain so-called Series A, B or C round of capital investments in order to bring your business to a higher level? If you are a business manager of an established company, are you looking into acquiring or licensing technology from, or otherwise investing in, a potential business partner? Or, if you are an individual investor, are you interested in gaining some insights into the mysterious private equity world? If you answer “yes” to any of the above, or if you are simply interested in learning something about the exciting Venture Capital investment world, this session is for you. This roundtable discussion session will provide opportunities for you to directly interact with and/or learn from eminent venture capitalists, business owners, corporate executives, and legal counsel on how to start, grow, or expand your businesses, how to place private equity investments, and how to avoid or minimize investment risks.

1:00 – 2:40 pm Wei Zhang, Entrepreneur in Residence, Lilly Asia Venture (礼来亚洲基金)

Jin Wang, CEO, Manhattan Capital (曼哈顿资本投资公司杭州公司)

Ji Li, EVP and Global Head of Business Development, BeiGene (百济神州)

Mike Liu, VP, Alphamab Co. Ltd (康宁杰瑞生物科技有限公司)

Lawrence Tian, CEO, Cifco USA (亚布力中国企业家论坛创始人主席)

Zhiqiang Fan, COO, BioClub (贝壳社)

Wansheng Jerry Liu, Partner - Intellectual Property, Fox Rothschild LLP

2:40 – 3:00 pm Coffee Break

Session C-2 SAPA Annual Chinese CEO Forum – Stories Beyond the News

The SAPA Chinese CEO Forum is a unique platform for education, discussion and debate around current and future challenges and opportunities in the pharmaceutical industry. This forum will explore how to craft actionable business strategies for competitive advantage. You will get to hear ideas, opinions, and solutions from successful CEOs both in US and China. Featured presentations will track the industry trends and provide projections and insights into future growth and development. It will also provide participants with strategic information needed as portfolios continue to advance and evolve. Topics will include healthcare policy and regulatory reform, economic models impacting the industry, current challenges in recruitment and talent development, successful recent M&A between U.S. and Chinese companies, and opportunities in unique and beneficial

5

partnership structures. There will be a round-table discussion after presentations for in-depth interaction with industry peers. You can ask real questions and get real answers.

3:00 – 5:00 pm Dahai Guo, Founder and CEO, PuraCap (人福普克药业)

Jinzi Wu, Founder and CEO, Ascletis (歌礼生物科技)

Dajun Yang, Founder, Chairman & CEO, Ascentage Pharma (亚盛医药)

Jingang Wang, CEO, Cosci-Med (北京科信必成医药)

Session D Capitalizing on Cutting-Edge Technologies and Global Industrial

Supports

Deluxe Executive Parior 158

We live in an age in which cutting edge technology is developing at a rapid speed and support for global pharmaceutical industry has grown tremendously. The presentations at this session of SAPA’s 2016 annual conference will focus on innovative technologies and platforms, including therapeutic protein redesign, antibody discovery platforms, precision medicine, companion diagnostics, industrial zones and incubators in both US and China, and full service CROs which cover all areas of pharmaceutical R&D. The following distinguished speakers from different companies will present:

1:00 – 1:25 pm Nelson Lee, President, Sunels Tech and Capital Corp (Session Sponsor) 1:25 – 1:50 pm Qingdong Xiao, Director, General Investment Promotion Bureau of Wuqing

District, Tianjin, China 1:50 – 2:15 pm Karl Griswold, CEO, Stealth Biologics 2:15 – 2:40 pm Neil Rosenberg, VP for Medical Affairs, Admera Health

2:40 – 3:00 pm Coffee Break

3:00 – 3:25 pm Zhonghai Li, CEO, CARsgen 3:25 – 3:50 pm Yangzhou Wang, VP, WuXi AppTec Lab Testing Division 3:50 – 4:15 pm James Jianguo Yang, CEO, Abpro China 4:15 – 4:40 pm Jim Huang, CEO, Ascendia Pharma

Session E Career Development Mini-Workshop - The Power of Mindset Shift

Hillsborough

Among all of the tools that can unleash the potential power for future success, which one is of universal and fundamental importance? “Mindset Shift”. This is a central starting point that can be the master key for unlocking many doors to success. Looking at things from a different perspective can often reveal hidden secrets and provide better solutions to career challenges. Building on participants’ individual intellectual strengths and respecting everyone’s different situation and needs, this session will first illustrate the benefit of mindset shift by using case studies and explore the hot topics that commonly occur during career development and advancement. After this session, the participants will bring home new solutions that will benefit their careers for many years to come.

6

1:00 – 5:00 pm John Sun, Global Project Manager, Novartis

Ling Kang, Lead Medical Writer, Daiichi Sankyo Sandy Suh, Head of R&D, Exeltis Howard Stamato, Associate Director, Drug Product Science and Technology, BMS

Session F Poster Session

1:30 – 5:30 pm Westfield

8:30 am – 4:30 pm Sponsors and Exhibition

Ballroom East and Prefunction Foyer

5:30 – 6:30 pm Reception Ballroom East

6:30 – 10:00 pm SAPA Annual Gala Dinner - Shanghai Pharmaceuticals Holding Co., Ltd. Night

Ballroom West and Center